Nuvation Bio (NYSE: NUVB) submitted a supplemental New Drug Application (sNDA) to the US FDA for Ibtrozi (taletrectinib), its next-generation ROS1 inhibitor, seeking to update the drug's label with extended follow-up data in adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The FDA has accepted the application and assigned a target action date of January 4, 2027.
The sNDA fulfills a post-marketing commitment tied to the original Ibtrozi FDA approval, which was granted in June 2025 following Priority Review and Breakthrough Therapy Designations for both first- and second-line or later settings. The current submission is not seeking a new indication but rather aims to update the efficacy information in the existing label with approximately 10 additional months of follow-up from the pivotal TRUST-I and TRUST-II studies, based on an August 2025 data cutoff.
The updated data package includes a median duration of response of 49.7 months and a median progression-free survival of 49.6 months in TKI-naive patients enrolled in TRUST-I, figures that correspond to more than four years of sustained clinical benefit. In the TRUST-II study, which enrolled both TKI-naive and TKI-pretreated patients globally, the median duration of response in TKI-pretreated patients was 19.4 months. Among TKI-naive patients in TRUST-II, the median duration of response had not been reached at the time of the data cutoff. Nuvation Bio said the safety profile observed at this extended follow-up remained consistent with prior reports, with no new signals identified.
TRUST-I and TRUST-II are Phase II single-arm, open-label, multicenter studies evaluating taletrectinib in adults with advanced ROS1-positive NSCLC. TRUST-I enrolled 173 patients in China, while TRUST-II enrolled 189 patients across global sites. Both studies used confirmed objective response rate assessed by an independent review committee as the primary endpoint. The updated data from these trials were presented at the American Association for Cancer Research Annual Meeting in 2026.
The ROS1-positive subset of NSCLC represents approximately 2% of the more than one million NSCLC cases diagnosed globally each year. The biology of this subtype carries a notable predisposition toward central nervous system involvement: roughly 35% of patients newly diagnosed with metastatic ROS1-positive disease have brain metastases at presentation, and approximately 50% of previously treated patients develop CNS metastases over the course of their disease. These features have made CNS penetration a central criterion in evaluating ROS1-directed therapies.
The treatment landscape for ROS1-positive NSCLC has expanded considerably since crizotinib became the first FDA-approved agent for this indication in 2016. Entrectinib followed in 2019, offering improved CNS activity. Repotrectinib, approved by the FDA in November 2023, introduced a macrocyclic design intended to address acquired resistance mutations, including the G2032R solvent-front mutation that commonly emerges after first-generation TKI therapy. Taletrectinib, which received full FDA approval in June 2025, is a selective, CNS-active inhibitor also engineered to retain activity against resistance mutations.